Pharmaceutical companies have made a habit of targeting the wrong cause (acetylcholinesterase inhibitors which are basically useless since as the disease progresses acetylcholinesterase activity declines by 85 percent), one aspect of the disease (Namenda as an antagonist for NMDA receptors), or insisting on a partially flawed mechanism for the disease (amyloid plaques).
Dr Golomb adds that patients with a low level of occupational exposure to acetylcholinesteraseinhibitors in agriculture for example through sheep-dipping or work in greenhouses report symptoms that mirror those of sick veterans.